AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill

News
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Rob Thornhill:

Good morning, my name is Rob Thornhill. I'm the CEO of Centricity Vision, the developer and manufacturer of ZEPTO and ZEPTOLink IOL positioning systems. Were excited to announce the commercial launch of our newest innovation, ZEPTOLink, here at the [American] Academy of Ophthalmology in San Francisco.

ZEPTOLink, as well as our legacy ZEPTO systems, are the first and only devices that create an instantaneous capsulotomy with precise 360 degree overlap and superior capsular edge strength, making our technology ideal for advanced technology intraocular lenses and complex cases, requiring enhanced precision. ZEPTOLink combines the clinically proven ZEPTO technology with any phacoemulsification device. This combination saves time and space in the operating room. A combination of 12 new and existing accounts, as well as 22 surgeons, participated in our soft launch over the last 3 months and successfully completed over 500 ZEPTOLink cases. The surgeons liked the intuitive use of the phaco foot pedal that allowed them to precisely control suction, energy delivery and irrigation. Universally, they recognise the enhanced speed of the ZEPTO system which leads to enhanced workflow efficiency, especially when compared to a laser system.

With the increasing cost of all goods and services, including cataract surgery, ZEPTO technology, at 1/10 the capital cost in one-half the per use cost of a laser, provide surgeons and their patients with a cost effective alternative when considering advanced technology IOL surgery. Thank you.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.